BioCentury
ARTICLE | Clinical News

Corvas reports Phase II anticoagulant data

September 14, 2000 7:00 AM UTC

CVAS said data from the largest cohort of unilateral knee replacement patients in a Phase II trial of rNAPc2 anticoagulant showed a greater than 50 percent reduction in deep vein thrombosis (DVT) comp...